UCB To Pay PDL $10M Over Antibody Patents
Belgian drugmaker UCB SA has agreed to pay PDL BioPharma Inc. $10 million to settle several patent disputes over UCB's rheumatoid arthritis treatment Cimzia in the U.S. and Europe, the companies...To view the full article, register now.
Already a subscriber? Click here to view full article